Inhibitor Therapeutics Inc.
INTI
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$3M
▲ +1.2% YoY
Op. Margin
–
ROIC
-3720.64%
▼ -177.3pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$3M
Net Debt
-$102K
Net Cash Position
Cash & Equiv.
$146K
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with INTI
Inhibitor Therapeutics (INTI) in three numbers
- Quality score
- 20/100
- Best check: share count change, -53.0%. Weakest: return on capital, -3720.6%.
- Quality
Questions about Inhibitor Therapeutics
Is Inhibitor Therapeutics a high-quality business?
Inhibitor Therapeutics scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from SEC filings. Its best check is share count change at -53.0%, and its weakest is return on capital at -3720.6%. The Quality tab shows every check against its target.
Does Inhibitor Therapeutics (INTI) pay a dividend?
No. Inhibitor Therapeutics (INTI) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 16 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 19 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in INTI's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing INTI
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.